MBOT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Microbot Medical Inc. (MBOT) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has a unique FDA-cleared product and positive analyst coverage, its financials show no revenue and significant losses. The technical indicators are neutral, and there are no strong trading signals or significant catalysts to suggest immediate upside. The stock is better suited for monitoring rather than immediate investment.
The MACD is positive but contracting, indicating a lack of strong momentum. RSI is neutral at 55.867, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 2.358, with resistance at 2.625 and support at 2.091.
The Liberty Endovascular Robotic System is the only FDA-cleared single-use robotic platform for peripheral vascular procedures.
Positive sentiment from B. Riley's Buy rating and $5 price target.
Stable operations and inventory despite geopolitical tensions.
Financials show no revenue and significant losses, with EPS dropping 65% YoY in Q3
Neutral sentiment from hedge funds and insiders, with no significant trading trends.
Stock trend analysis predicts a potential decline in the next week (-2.31%).
In Q3 2025, the company reported no revenue growth, a net loss of $3.58M (up 11.26% YoY), and a 65% YoY drop in EPS to -0.07. Gross margin remains at 0%.
B. Riley initiated coverage with a Buy rating and a $5 price target, citing the company's unique position with the only FDA-cleared robotic system and its potential for faster commercial traction compared to peers.
